<DOC>
	<DOCNO>NCT00776425</DOCNO>
	<brief_summary>This 2 arm study investigate Quality Life response anemic patient solid lymphoid malignancy , receive concomitant chemotherapy . Patients treatment Arm 1 solid lymphoid malignancy receive NeoRecormon dose 150 IU/kg three time weekly . Patients treatment Arm 2 lymphoid malignancy receive NeoRecormon 30,000 IU s.c. weekly . The anticipated time study treatment 1 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Quality Life Treatment Response Once Weekly NeoRecormon ( Epoetin Beta ) Treatment Anemic Patients With Solid Lymphoid Malignancies .</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>male female patient ; &gt; =18 year age ; anemia prescribe treatment NeoRecormon ; confirm diagnosis solid lymphoid hematologic malignancy ; receive schedule receive chemotherapy ; life expectancy &gt; =6 month . anemia bleeding , hemolytic anemia , megaloblastic anemia , anemia chronic kidney failure , lever endocrinology disease ; contraindication NeoRecormon ; administration NeoRecormon chemotherapy ( e.g . third day chemotherapy cycle start ) ; bleed within one month and/or study ; severe infection within one month and/or study ; inability patient fill questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>